Source comparison
Comparison: Tesamorelin Response Timeline vs Other Research Peptides
Tesamorelin GHRH receptor agonist → pituitary GH release → hepatic IGF-1 production GH elevation within 2–4 hours; IGF-1 plateau at 7–14 days VAT reduction detectable at 12 weeks, significant at 26 weeks 26 weeks for body composition endpoints Best-in-class fo
This comparison does not assign a generated winner or score.
- Tesamorelin
- GHRH receptor agonist → pituitary GH release → hepatic IGF-1 production
- GH elevation within 2–4 hours; IGF-1 plateau at 7–14 days
- VAT reduction detectable at 12 weeks, significant at 26 weeks
- 26 weeks for body composition endpoints
- Best-in-class for visceral fat studies; dual-phase timeline requires careful endpoint selection
- CJC-1295 (DAC)
- GHRH analogue with extended half-life (6–8 days)
- GH elevation sustained over 7–14 days per injection
- IGF-1 plateau similar to tesamorelin; body composition changes at 12–20 weeks
- 12–16 weeks for lean mass or fat loss
- Longer dosing intervals reduce injection frequency; similar outcome timeline to tesamorelin
- Ipamorelin
- Ghrelin mimetic (GHSR agonist)
- GH pulse within 30–60 minutes; shorter half-life (2 hours)
- Requires daily dosing; body composition effects at 8–16 weeks
- 12 weeks minimum
- Faster GH pulse but shorter duration; less robust for VAT-specific studies
- Sermorelin
- Endogenous GHRH (1-29 fragment)
- GH response within 1–2 hours; shorter half-life than tesamorelin
- Body composition effects require 16–24 weeks sustained use
- 16–24 weeks
- Original GHRH peptide; pharmacokinetics less favourable than tesamorelin analogues